Puma Biotechnology (PBYI)
Commercializes NERLYNX for HER2-positive breast cancer and develops alisertib.
3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc.
BlackRock Inc. bought a new stake in Puma Biotechnology, Inc. (NASDAQ: PBYI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,804,736 shares of the biopharmaceutical company's stock, valued at approximately $30,856,000. BlackRock Inc. owned 7.47% of
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology Q2 Earnings Call Highlights
Puma Biotechnology NASDAQ: PBYI reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net income of $8.2 million, or $0.16 per diluted share, compared with a net loss of $3.8 million, or $0.07 per share, in the first quarter.
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.15 per share a year ago.
Puma Biotechnology Reports Second Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call beginning at 1:30 p.m. PT on Aug. 6, following release of its earnings results for 2Q-2026.
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on August 6, 2026, following release of its 2Q-2026 results.
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook boost investor confidence.
Puma Biotechnology Q1 Earnings Call Highlights
Puma Biotechnology NASDAQ: PBYI reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, according to remarks on the company's earnings call. Management attributed the quarter's product revenue performance in part to a specialty pharmacy and distributor inventory drawdown and highlighted new interim clinical data from ongoing Phase II alisertib studies in small cell lung cancer and HER2-negative, hormone receptor-positive breast cancer.
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Puma Biotech (PBYI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to earnings of $0.1 per share a year ago.
Gun Makers Reach Cooperation Pact After Months of Tense Proxy Battle
Under the terms of their new agreement, Beretta may increase its investment in Sturm, Ruger to up to 25% of outstanding shares, including a tender offer at a minimum of $44.80 a share.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call on May 7 at 1:30 p.m. PT, following release of its first quarter 2026 financial results.
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average – Should You Sell?
Puma Biotechnology, Inc. (NASDAQ: PBYI - Get Free Report) shares passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $5.76 and traded as high as $6.23. Puma Biotechnology shares last traded at $6.13, with a volume of 182,822 shares traded. Analyst Ratings Changes Several analysts recently
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript